Real‐world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada
Journal of Viral Hepatitis · 2024
DOI: 10.1111/jvh.13931 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2024. Verfasst von B Wolfson-Stofko und 9 weiteren Autor:innen. Beteiligte Einrichtung: Viral Hepatitis Care Network (VIRCAN), Toronto Centre for Liver Disease, University Health Network, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Hepatitis C, Substance Abuse, Intravenous. Die Arbeit nennt 60 Literaturangaben. Gefördert von: Viral Hepatitis Care Network (VIRCAN).
Abstract (Originalsprache)
Widespread screening for hepatitis C virus (HCV) is necessary for Canada to meet its HCV elimination goals by 2030. People who currently or previously injected drugs are at high risk for HCV. Opioid agonist therapy (OAT, such as methadone and buprenorphine) has been shown to help stabilize the lives of people who are opioid‐dependent. The distribution of OAT in North America typically requires daily, weekly, or monthly clinic visits and presents an opportunity for engagement, screening and treatment for those at high‐risk of HCV. In this study, HCV screening was conducted by staff at OAT clinics in Ontario from 2016 to 2020 and those with chronic infections were treated on‐site with direct‐acting antivirals. Point‐of‐care or dried blood spot (DBS) testing was used for antibodies, DBS or serum for HCV RNA and serum for HCV RNA at SVR12 (sustained virological response). Clinics screened 1954 people (mean age 40 years ±12, 63% male). Forty‐five percent were antibody positive, of whom 64% were HCV RNA+. Eighty percent of those RNA+ set an appointment in which 99% attended. Ninety‐six percent started treatment with 87% completing treatment. Sixty‐eight percent of people who completed treatment submitted a sample for SVR12 testing of which 97% achieved a virological cure. Results suggest that HCV screening and treatment at OAT clinics is feasible, effective and warrants expansion. Data suggest strong treatment adherence due to high rates of SVR12 comparable with other OAT‐based HCV treatment programs. The lack of SVR12 sampling could be addressed by either on‐site phlebotomy or incentivizing SVR12 sampling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Viral Hepatitis Care Network (VIRCAN), Toronto Centre for Liver Disease, University Health Network, Toronto, Ontario, Canada.
- Center for Drug Use and HIV/HCV Research (CDUHR), College of Global Public Health, New York University, New York, New York, USA.
- School of Nursing, York University, Toronto, Ontario, Canada.
- Division of Gastroenterology & Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands.
- Department of Epidemiology, Biostatistics, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
- Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Förderung
- Viral Hepatitis Care Network (VIRCAN)
Zitieren
APA
Wolfson-Stofko, B., Hirode, G., Vanderhoff, A., Karkada, J., Capraru, C., Biondi, M. J., Hansen, B., Shah, H., Janssen, H. L. A., & Feld, J. J. (2024). Real‐world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13931
Vancouver
Wolfson-Stofko B, Hirode G, Vanderhoff A, Karkada J, Capraru C, Biondi MJ, et al. Real‐world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada. Journal of Viral Hepatitis. 2024. doi:10.1111/jvh.13931
BibTeX
@article{WolfsonStofko2024,
author = {Wolfson-Stofko, B and Hirode, G and Vanderhoff, A and Karkada, J and Capraru, C and Biondi, M J and Hansen, B and Shah, H and Janssen, H L A and Feld, J J},
title = {Real‐world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada},
journal = {Journal of Viral Hepatitis},
year = {2024},
doi = {10.1111/jvh.13931}
}
EUVIMED